Radient Pharmaceuticals Corporation fka RXPC

[primarywatcher]

NuVax has "full rights to CIT", according to RPC's press release dated 1/25/2011: http://www.radient-pharma.com/pdf/press_releases/2011/012511%20NV_UFlorida%20license.pdf

Dr. LungJi Chang also developed the Combined Immunogene Therapy (“CIT”) a patented (patent issued May 25, 2004) cancer therapy owned by NuVax. CIT is a novel immunegene therapy that works by simultaneously incorporating two genes directly into the patient's tumor cells to enhance their immune system’s natural ability to destroy other cancer cells. CIT targets cancer cells for immunological attack, while simultaneously stimulating a stronger immune response against the tumor cells. Dr. Chang serves as an advisor to NuVax for the continued development of CIT and other gene therapies. NuVax has full rights to CIT.

Apparently negotiations began with the "creation" of NuVax on 12/7/2010:
http://www.researchviews.com/healthcare/pharma/gastroenterology/NewsReport.aspx?sector=Gastroenterology&ArticleID=362853

The formation of NuVax is a strategic move on the part of RPC to enhance the company’s second quarter of 2010 collaboration agreement with US-based Jaiva Technologies - a biotechnology company engaged in the research and development, distribution, marketing and sales of thirdparty healthcare technology products.

NuVax, a clinical stage pharmaceutical company, aims to develop new immunegene therapeutics that have the potential to significantly impact and extend the quality of life for cancer patients. Through the newly formed NuVax, RPC and Jaiva Technologies will utilize RPC’s combined immunogene therapy (CIT) cancer therapy to carry out human phase II clinical trials and develop products that will be first inline therapies for largely unmet medical needs for cancer.

The rights to RPC’s CIT technology are anticipated to be transferred to NuVax and 100% of future product development and commercialization, including the development and inlicensing of the up to five additional cancerfighting technologies will be managed through NuVax under the leadership of Jaiva Technologies founder, president and CEO Umesh Bhatia.

;) so we have ONE EXCLUSIVE agreement with the University of Florida to commercialize the huge success of CIT...

RPC... Wow, bang a drum. eh, one bang will do - let's not draw too much attention to details. lol!